UOC
IMCR icon

UBS O'Connor’s Immunocore IMCR Stock Holding History

UBS O'Connor’s Portfolio IMCR Stock Details IMCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-17,500
Closed -$42.9K – 394
2024
Q4 		$42.9K Buy
+17,500
New +$553K ﹤0.01% 369
2024
Q1 		– Sell
-25,000
Closed -$340K – 557
2023
Q4 		$340K Buy
+25,000
New +$1.3M 0.01% 382

Other funds holding IMCR

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

UBS O'Connor's IMCR Position: Q3 2025 in Review

UBS O'Connor sold out of Immunocore (IMCR) in Q3 2025, closing a stake of 53,343 shares — an estimated $1.67M sold.

UBS O'Connor first reported a position in IMCR in Q1 2022 and held it in 14 quarters. The position peaked at $2.42M in Q2 2023. 132 funds tracked by Wall St. Rank hold IMCR as of Q3 2025.

  • UBS O'Connor reported no remaining Immunocore position as of Q3 2025 after selling out during the quarter.
  • UBS O'Connor sold 53,343 Immunocore shares in Q3 2025, an estimated $1.67M.
  • UBS O'Connor first reported a position in Immunocore in Q1 2022 and held it in 14 quarters.
  • UBS O'Connor's Immunocore position peaked at $2.42M in Q2 2023.
  • 132 funds tracked by Wall St. Rank held Immunocore as of Q3 2025.

Based on UBS O'Connor's 13F filing for Q3 2025, filed 14 Nov 2025.